Corbus Pharmaceuticals Analyst Ratings
Corbus Pharmaceuticals Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/09/2023 | 241.61% | Oppenheimer | → $22 | Reiterates | Outperform → Outperform |
| 05/10/2023 | 241.61% | Oppenheimer | → $22 | Upgrades | Perform → Outperform |
| 03/08/2023 | -53.42% | HC Wainwright & Co. | → $3 | Reiterates | → Buy |
| 02/14/2023 | -53.42% | HC Wainwright & Co. | → $3 | Reiterates | → Buy |
| 10/08/2020 | -53.42% | HC Wainwright & Co. | $6 → $3 | Maintains | Buy |
| 09/09/2020 | -6.83% | HC Wainwright & Co. | $24 → $6 | Maintains | Buy |
| 09/08/2020 | — | Roth Capital | Downgrades | Buy → Neutral | |
| 09/08/2020 | — | BTIG | Downgrades | Buy → Neutral | |
| 09/08/2020 | — | RBC Capital | Downgrades | Outperform → Sector Perform | |
| 06/17/2020 | 241.61% | BTIG | → $22 | Initiates Coverage On | → Buy |
| 06/04/2020 | 396.89% | Nomura | $12 → $32 | Maintains | Buy |
| 03/26/2020 | 1639.13% | Nomura | → $112 | Initiates Coverage On | → Buy |
| 04/05/2019 | 179.5% | Jefferies | → $18 | Initiates Coverage On | → Buy |
| 03/19/2019 | 334.78% | Oppenheimer | → $28 | Initiates Coverage On | → Outperform |
| 12/26/2018 | 272.67% | HC Wainwright & Co. | → $24 | Initiates Coverage On | → Buy |
| 12/07/2018 | 257.14% | RBC Capital | → $23 | Initiates Coverage On | → Outperform |
| 10/24/2018 | 241.61% | B. Riley Securities | → $22 | Initiates Coverage On | → Buy |
| 09/14/2018 | 459.01% | Cantor Fitzgerald | $32 → $36 | Maintains | Overweight |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 08/09/2023 | 241.61% | 奧本海默 | → 22 美元 | 重申 | 跑贏大盤 → 跑贏大盤 |
| 05/10/2023 | 241.61% | 奧本海默 | → 22 美元 | 升級 | 表現 → 跑贏大盤 |
| 03/08/2023 | -53.42% | HC Wainwright & Co. | → 3 美元 | 重申 | → 購買 |
| 02/14/2023 | -53.42% | HC Wainwright & Co. | → 3 美元 | 重申 | → 購買 |
| 2020 年 8 月 10 日 | -53.42% | HC Wainwright & Co. | 6 美元 → 3 美元 | 維護 | 購買 |
| 2020 年 9 月 9 日 | -6.83% | HC Wainwright & Co. | 24 美元 → 6 美元 | 維護 | 購買 |
| 2020 年 8 月 9 日 | — | 羅斯資本 | 降級 | 買入 → 中性 | |
| 2020 年 8 月 9 日 | — | BTIG | 降級 | 買入 → 中性 | |
| 2020 年 8 月 9 日 | — | 加拿大皇家銀行資本 | 降級 | 跑贏大盤 → 行業表現 | |
| 2020 年 6 月 17 日 | 241.61% | BTIG | → 22 美元 | 啓動覆蓋開啓 | → 購買 |
| 06/04/2020 | 396.89% | 野村 | 12 美元 → 32 美元 | 維護 | 購買 |
| 2020 年 3 月 26 日 | 1639.13% | 野村 | → 112 美元 | 啓動覆蓋開啓 | → 購買 |
| 2019 年 5 月 4 日 | 179.5% | 傑富瑞 | → 18 美元 | 啓動覆蓋開啓 | → 購買 |
| 03/19/2019 | 334.78% | 奧本海默 | → 28 美元 | 啓動覆蓋開啓 | → 跑贏大盤 |
| 12/26/2018 | 272.67% | HC Wainwright & Co. | → 24 美元 | 啓動覆蓋開啓 | → 購買 |
| 2018 年 7 月 12 日 | 257.14% | 加拿大皇家銀行資本 | → 23 美元 | 啓動覆蓋開啓 | → 跑贏大盤 |
| 2018 年 10 月 24 日 | 241.61% | B. 萊利證券 | → 22 美元 | 啓動覆蓋開啓 | → 購買 |
| 09/14/2018 | 459.01% | 坎託·菲茨傑拉德 | 32 美元 → 36 美元 | 維護 | 超重 |
What is the target price for Corbus Pharmaceuticals (CRBP)?
Corbus Pharmicals（CRBP）的目標價格是多少？
The latest price target for Corbus Pharmaceuticals (NASDAQ: CRBP) was reported by Oppenheimer on August 9, 2023. The analyst firm set a price target for $22.00 expecting CRBP to rise to within 12 months (a possible 241.61% upside). 4 analyst firms have reported ratings in the last year.
奧本海默於2023年8月9日公佈了Corbus Pharmicals（納斯達克股票代碼：CRBP）的最新目標股價。這家分析公司將目標股價定爲22.00美元，預計CRBP將在12個月內升至241.61％（可能上漲241.61％）。去年有4家分析公司公佈了評級。
What is the most recent analyst rating for Corbus Pharmaceuticals (CRBP)?
Corbus Pharmicals（CRBP）的最新分析師評級是多少？
The latest analyst rating for Corbus Pharmaceuticals (NASDAQ: CRBP) was provided by Oppenheimer, and Corbus Pharmaceuticals reiterated their outperform rating.
Corbus Pharmicals（納斯達克股票代碼：CRBP）的最新分析師評級由奧本海默提供，Corbus Pharmicals重申了其表現跑贏大盤的評級。
When is the next analyst rating going to be posted or updated for Corbus Pharmaceuticals (CRBP)?
Corbus Pharmicals（CRBP）的下一個分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Corbus Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Corbus Pharmaceuticals was filed on August 9, 2023 so you should expect the next rating to be made available sometime around August 9, 2024.
分析師在進行了廣泛的研究（包括瀏覽公開財務報表、與Corbus Pharmicals的高管和客戶交談以及聽取業績電話會議）後得出了股票評級。大多數分析師每三個月進行一次評級，因此每家公司每年應該獲得4個評級。Corbus Pharmicals的最新評級是在2023年8月9日提交的，因此您應該預計下一個評級將在2024年8月9日左右公佈。
Is the Analyst Rating Corbus Pharmaceuticals (CRBP) correct?
分析師對Corbus Pharmicals（CRBP）的評級正確嗎？
While ratings are subjective and will change, the latest Corbus Pharmaceuticals (CRBP) rating was a reiterated with a price target of $0.00 to $22.00. The current price Corbus Pharmaceuticals (CRBP) is trading at is $6.44, which is within the analyst's predicted range.
儘管評級是主觀的，將會發生變化，但最新的Corbus Pharmicals（CRBP）評級得到了重申，目標股價爲0.00美元至22.00美元。Corbus Pharmicals（CRBP）目前的交易價格爲6.44美元，在分析師的預測區間內。
譯文內容由第三人軟體翻譯。